Swedish Orphan Biovitrum EBIT Margin 2019-2025 | BIOVF

Swedish Orphan Biovitrum ebit margin for the quarter ending June 30, 2025 was 22.36%.

  • Swedish Orphan Biovitrum average ebit margin for 2024 was 19.4%, a 9.56% increase from 2023.
  • Swedish Orphan Biovitrum average ebit margin for 2023 was 21.45%, a 6.14% decline from 2022.
  • Swedish Orphan Biovitrum average ebit margin for 2022 was 20.21%, a 26.16% increase from 2021.

Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues

Swedish Orphan Biovitrum EBIT Margin 2019-2025 | BIOVF

  • Swedish Orphan Biovitrum average ebit margin for 2024 was 19.4%, a 9.56% increase from 2023.
  • Swedish Orphan Biovitrum average ebit margin for 2023 was 21.45%, a 6.14% decline from 2022.
  • Swedish Orphan Biovitrum average ebit margin for 2022 was 20.21%, a 26.16% increase from 2021.

Ebit margin can be defined as earnings before interest and taxes as a portion of total revenues
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$247.8B
Amgen (AMGN)$154.9B
Gilead Sciences (GILD)$140.2B
Vertex Pharmaceuticals (VRTX)$100.3B
Bristol Myers Squibb (BMY)$96B
GSK (GSK)$80.8B
CSL (CSLLY)$67.1B
Regeneron Pharmaceuticals (REGN)$61.5B
Alnylam Pharmaceuticals (ALNY)$58.5B
Argenex SE (ARGX)$43.6B
Insmed (INSM)$28.8B
BioNTech SE (BNTX)$24B
Royalty Pharma (RPRX)$21B
Biogen (BIIB)$19.4B
Incyte (INCY)$16.5B
Genmab (GNMSF)$16.5B
Genmab (GMAB)$16B
Illumina (ILMN)$15.4B
Ascendis Pharma (ASND)$11.9B
BioMarin Pharmaceutical (BMRN)$11.2B
QIAGEN (QGEN)$10.3B
Exelixis (EXEL)$10.1B
Moderna (MRNA)$9.4B
Verona Pharma American Depositary Share (VRNA)$9.2B
Exact Sciences (EXAS)$9B
Bio-Techne Corp (TECH)$8.6B
Halozyme Therapeutics (HALO)$8.6B
Guardant Health (GH)$8.4B
Blueprint Medicines (BPMC)$8.3B
Roivant Sciences (ROIV)$8.1B